Actively Recruiting
Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination
Led by Oregon Health and Science University · Updated on 2025-07-31
35
Participants Needed
1
Research Sites
126 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to assess the immune response to the yellow fever vaccine 17D in adults with prior 17D vaccination. The main questions this study aims to answer are: * how does prior vaccination affect antibody responses to re-vaccination? * how does prior vaccination affect the immune cell response to re-vaccination? Participants will: * have been previously vaccinated with 17D. * be re-vaccinated with 17D. * provide medical and travel histories. * provide a blood sample prior to vaccination * provide a blood sample approximately every other day for 14 days after vaccination. * provide a blood sample approximately 28 days after vaccination. * complete a daily diary of symptoms following vaccination for 14 days. * report any additional symptoms after 14 days.
CONDITIONS
Official Title
Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 20 to less than 50 years
- Male or female
- In good health as determined by medical history and physical exam
- Documented yellow fever vaccination at least 8 years prior with official records
- Able to comply with all trial procedures and follow-up
You will not qualify if you...
- Active infection or fever of 38°C (100.4°F) or higher within 3 days before vaccination
- Allergy or hypersensitivity to vaccine components including eggs
- Behavioral or cognitive impairment affecting safe participation
- History of neurological disorders, seizures, or neuro-inflammatory disease
- Illness that may interfere with the trial or increase risk
- Immune system impairment or use of immunosuppressive therapies within defined timeframes
- History of splenic or thymic dysfunction
- Serious chronic or progressive diseases (e.g., cancer, diabetes, heart, kidney, liver disease)
- Body Mass Index of 35 kg/m2 or higher
- Participation in other clinical trials with investigational products within 30 days
- Recent vaccination within 14 days (inactivated) or 28 days (live) before enrollment
- Use of antipyretics or pain medicines within 24 hours before vaccination
- History of substance or alcohol abuse within past 2 years
- Pregnant or breastfeeding
- Sexually active women of childbearing potential not using acceptable contraception for at least 2 months prior
- Refusal to use contraception for 28 days after vaccination if sexually active
- Positive or unclear pregnancy test
- Planned vaccination against other diseases during the trial
- Planned travel to yellow fever endemic areas during the trial
- Positive screening tests for dengue, zika, West Nile, or Japanese encephalitis viruses
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Oregon Health & Science University
Portland, Oregon, United States, 97239
Actively Recruiting
Research Team
W
William Messer, MD PhD
CONTACT
S
Sarah Siegel, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here